...
机译:碳酸镧的成本效益处理高磷血症在慢性肾脏疾病透析之前和期间
Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics (PE2), University of;
Tolley Health Economics Ltd, Buxton, United Kingdom;
Shire Pharmaceuticals Group, Wayne, PA, United States;
lanthanum carbonate; Hyperphosphatemia; Chronic Kidney DiseasesCost EffectivenessEnd Stage Kidney Diseasephosphate binder agentsVFM;
机译:Lanthanum carbonate for hyperphosphatemia in patients with advanced CKD and patients receiving dialysis
机译:Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations
机译:Prevention and treatment of hyperphosphatemia in chronic kidney disease
机译:Cardiac Event Risk in Japanese subjects Estimated Using Gated myocardial perfusion Imaging, in Conjunction With Diabetes mellitus and Chronic Kidney Disease